about
A case of PHACE syndrome.The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonatesA randomized, controlled trial of oral propranolol in infantile hemangioma.Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).Atopic eczema: its impact on the family and financial costAdverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement.A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients.Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14.Dressings used in epidermolysis bullosa blister wounds: a review.Sweet's syndrome with postinflammatory elastolysis and Takayasu arteritis in a child: a case report and literature review.Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.Association Between Discoid Lupus Erythematosus and Chronic Granulomatous Disease--Report of Two Cases and Review of the Literature.A Review of 52 Pedigrees with Epidermolysis Bullosa Simplex Identifying Ten Novel Mutations in KRT5 and KRT14 in Australia.Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age.When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice.Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa.Unsuspected allergic contact dermatitis to alcohol swabs following neurosurgery.Screening for Sturge-Weber syndrome: A state-of-the-art review.Consensus statement for the treatment of infantile haemangiomas with propranolol.A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study.Determining Effects of Superfine Sheep wool in INfantile Eczema (DESSINE): a randomized paediatric crossover study.The skin as a target for prevention of the atopic march.Common rashes in neonates.CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.IgE food sensitization in infants with eczema attending a dermatology department.Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia.Multiple clustered dermatofibroma presenting in a segmental distribution.Debunking the Myth of Wool Allergy: Reviewing the Evidence for Immune and Non-immune Cutaneous ReactionsPEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategyVaried presentations of pseudoxanthoma elasticum in a familyAutosomal dominant bullous dermolysis of the newborn associated with a heterozygous missense mutation p.G1673R in type VII collagenInfantile acne in a 2-year-old boyEosinophilic perimyositis manifesting as localized urticariaSkin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of CareSuccessful re-introduction of vitamin B12 after using isotretinoin to treat severe acne medicamentosaRetrospective review of screening for Sturge-Weber syndrome with brain magnetic resonance imaging and electroencephalography in infants with high-risk port-wine stainsSafety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
P50
Q33224362-4DDAA0BA-9A5B-45F7-8F6C-D4BEABE45056Q33626137-368B84F1-64E8-41F0-BFFE-3445E8A0ED29Q34218186-48EBE5DE-E341-4235-BD06-FCC10D7173EFQ34668015-45D9882F-52B4-40F6-9301-C360C0EFCFFDQ35072028-47241BE2-0DF2-4753-9C6F-66F5FBD5BF54Q35254482-19BE0AF2-0E64-497E-8FFD-25BF7595FED1Q35573947-1EEA29CC-44CE-4C16-960B-EE11F9F0A606Q36232707-1D71C0B9-35E1-4A2F-A384-BA8531FD3CDEQ36707108-14B77164-8E92-4B49-BF60-F29FB99EDFAAQ37247277-B47AC8D0-C7A1-49A6-AD53-5DC18A507ADAQ37315312-387EA5B5-CBB5-4FC3-85F9-3721C8C62537Q37947380-6392FB98-819B-47EC-BF1B-A0093460299CQ38104769-C66EED7B-6BE7-4A53-BB0F-DABA49F2CC48Q38784163-BFBA3E81-8644-486F-A9B3-F8506FA13F72Q39340580-EAC93985-6E57-4C49-B8C0-3EF547D252D0Q40064982-AC17F955-94E4-4E92-864D-1566A08DC99DQ40095599-A8C68FBE-1FE9-4815-84F9-62AB383F3004Q40539910-930F2607-A41C-433A-99DA-578D25AEB3BFQ43550606-97975122-2BA2-47A1-803C-58D9A1FBE7BDQ47821693-95C69F53-3700-47B7-A284-319B602CF635Q48017347-C65EB725-38C9-4DD5-8B8A-1688420D1275Q48174382-1F786B6F-9EEC-403D-98EB-D16DEC5900ACQ48238458-91815887-F2CE-403F-94B9-9767E665FEF3Q48257149-C8D34E29-EF1C-48D8-8E41-4A14169BC860Q50138859-F9A0516A-7F70-4772-82AA-27DC5124D1C0Q50511733-5EEC7AB5-5FFE-4982-B663-5CF46FBE67B4Q52686801-7D6E8B66-7547-4E4B-B637-47F260C240C1Q53027917-4A4CC678-DD2E-4625-8361-2C5A5D60CD7DQ53100162-CDB40A61-1FC4-4FC8-99A7-3D89FBA46ECAQ53653389-92E72A2A-55BC-49B3-B210-CAE70959B6C5Q59153972-83A9DE8D-BF0B-4A17-9876-3EBF4320639EQ64097094-0ED52AA1-CA1B-4602-AE40-8F42BAF8FD89Q79346626-DD86F405-4897-4272-86AB-C23704953DB2Q82443773-49B513C4-99A3-4442-B2AD-E32FEBF1828BQ84919894-D5711629-CED1-4B52-B7FD-763C6A5837CEQ86075497-D25894E3-7E5B-410F-AECC-0BB07D0A4C70Q88463151-F2E49F11-F0AE-4C7A-8B53-D32D0BF82051Q89085942-3F4D5525-53EA-4738-B538-C435E4158143Q90313444-B5F28F22-9B77-4C18-9B51-3AF843467CAFQ90648525-E8463011-20C9-4C39-B08A-E4C038A35F10
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John C. Su
@ast
John C. Su
@en
John C. Su
@es
John C. Su
@nl
John C. Su
@sl
type
label
John C. Su
@ast
John C. Su
@en
John C. Su
@es
John C. Su
@nl
John C. Su
@sl
prefLabel
John C. Su
@ast
John C. Su
@en
John C. Su
@es
John C. Su
@nl
John C. Su
@sl
P1053
E-6040-2017
P106
P1153
55177552100
57001873900
P21
P31
P3829
P496
0000-0002-4021-5423